Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1449858 | 0.94 | TDP1 (0.63) | LMNATDP1MAPK1HIF1ASLC6A2 | |
| Hydrochloric Acid SCHEMBL20641020 | 0.92 | TDP1 (0.61) | LMNATDP1MAPK1HIF1ASLC6A2 | |
| Hydrochloric Acid SCHEMBL7424170 | 0.92 | TDP1 (0.61) | LMNATDP1MAPK1HIF1ASLC6A2 | |
| Water SCHEMBL27902319 | 0.92 | TDP1 (0.61) | LMNATDP1MAPK1HIF1ASLC6A2 | |
| Trifluoroacetic Acid SCHEMBL7424326 | 0.83 | MAPK1 (0.55) | LMNATDP1MAPK1HIF1ASLC6A2 | |
| Trifluoroacetic Acid SCHEMBL7423789 | 0.83 | MAPK1 (0.55) | LMNATDP1MAPK1HIF1ASLC6A2 | |
| SCHEMBL28360388 | 0.83 | LMNA (0.54) | LMNATDP1MAPK1HIF1ASLC6A2 | |
| SCHEMBL27833464 | 0.82 | KDM4E (0.69) | LMNATDP1MAPK1HIF1ASLC6A2 | |
| Ethyl Benzoate SCHEMBL28486260 | 0.82 | LMNA (0.66) | LMNATDP1MAPK1HIF1ASLC6A2 | |
| SCHEMBL27350238 | 0.82 | LMNA (0.50) | LMNATDP1SLC6A2KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838299-B2 | Lanthanide complexes, preparation and uses thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-11-23 | — | — | US | disclosed |
| US-20100216252-A1 | Lanthanide Complexes, Preparation and Uses Thereof | UNIVERSITE LOUIS PASTEUR DE STRASBOURG (FR) | 2010-08-26 | — | — | US | disclosed |
| US-7709263-B2 | Lanthanide complexes preparation and uses thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-05-04 | — | — | US | disclosed |
| US-20080044923-A1 | Lanthanide Complexes Preparation and Uses Thereof | UNIVERSITE LOUIS PASTEUR DE STRASBOURG (FR) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044923-A1 | Lanthanide Complexes Preparation and Uses Thereof | NR2E3, GALR3, NR0B2 | ADRB2 733/4885LMNA 269/4885TDP1 4710/4885 |
| US-20100216252-A1 | Lanthanide Complexes, Preparation and Uses Thereof | NR2E3, NR0B2, GALR3 | ADRB2 640/4885LMNA 281/4885TDP1 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.